Valuation: Fresenius

Market Cap 22.48B 25.59B 20.72B 19.39B 36.31B 2,414B 37.08B 249B 96.39B 1,191B 96.08B 93.97B 4,139B P/E 2026 *
11.9x
P/E 2027 * 10.7x
Enterprise Value 32.83B 37.37B 30.26B 28.31B 53.03B 3,525B 54.16B 364B 141B 1,740B 140B 137B 6,045B EV / Sales 2026 *
1.39x
EV / Sales 2027 * 1.29x
Free-Float
72.99%
Yield 2026 *
2.85%
Yield 2027 * 3.1%
Manager TitleAgeSince
Chief Executive Officer 57 01/10/2022
Director of Finance/CFO 46 01/09/2022
Compliance Officer 50 -
Director TitleAgeSince
Director/Board Member 71 20/05/2015
Director/Board Member 65 13/05/2016
Director/Board Member 52 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 25.72B
-0.31%+6.12%+57.21%+49.91% 134B
+1.22%+4.40%+4.67%+32.59% 85.84B
+1.76%+7.63%+17.48%+48.34% 22.83B
-0.09%-1.97%-18.15%-25.30% 19.93B
+2.75%+9.52%+11.83%+141.69% 15.84B
+1.00%+3.30%-1.89%+5.09% 14.65B
+1.72%+4.39%+54.63%+122.08% 13.7B
-0.07%-0.97%-13.96%-8.88% 12.5B
+3.86%+2.92%-9.32%+93.96% 11.58B
Average +1.18%+3.17%+11.39%+51.05% 36.71B
Weighted average by Cap. +0.64%+4.37%+26.34%+45.49%

Financials

2026 *2027 *
Net sales 23.62B 26.89B 21.77B 20.37B 38.15B 2,537B 38.97B 262B 101B 1,252B 101B 98.75B 4,350B 24.83B 28.27B 22.89B 21.42B 40.11B 2,667B 40.97B 275B 106B 1,316B 106B 104B 4,573B
Net income 1.89B 2.16B 1.75B 1.63B 3.06B 203B 3.13B 21.01B 8.12B 100B 8.1B 7.92B 349B 2.12B 2.42B 1.96B 1.83B 3.43B 228B 3.5B 23.53B 9.1B 112B 9.07B 8.87B 391B
Net Debt 10.35B 11.78B 9.54B 8.93B 16.72B 1,111B 17.07B 115B 44.38B 548B 44.23B 43.26B 1,906B 9.6B 10.93B 8.85B 8.28B 15.51B 1,031B 15.84B 106B 41.16B 509B 41.03B 40.13B 1,768B
Logo Fresenius
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (59.2%; Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (37.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc.; - other (3.1%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
40.11EUR
Average target price
54.22EUR
Spread / Average Target
+35.18%

Quarterly revenue - Rate of surprise